



Universiteit
Leiden

The Netherlands

Schistosoma mansoni extracellular vesicles and their impact on the immune system: glycosylated messengers in host-pathogen communication

Kuipers, M.E.

Citation

Kuipers, M. E. (2024, September 25). *Schistosoma mansoni extracellular vesicles and their impact on the immune system: glycosylated messengers in host-pathogen communication*. Retrieved from <https://hdl.handle.net/1887/4092867>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4092867>

Note: To cite this publication please use the final published version (if applicable).



Chapter 4

Life stage-specific glycosylation of extracellular vesicles from *Schistosoma mansoni* schistosomula and adult worms drives differential interaction with C-type lectin receptors DC-SIGN and MGL

Marije E. Kuipers, D. Linh Nguyen, Angela van Diepen,

Lynn Mes, Erik Bos, Roman I. Koning, Esther N.M.

Nolte-'t Hoen, Hermelijn H. Smits*, Cornelis H. Hokke*

*These authors contributed equally to this study

Frontiers in Molecular Biosciences, 2023

PMID: 37006612

DOI : 10.3389/fmolb.2023.1125438

Abstract

Schistosomes can survive in mammalian hosts for many years, and this is facilitated by released parasite products that modulate the host's immune system. Many of these products are glycosylated and interact with host cells via C-type lectin receptors (CLRs). We previously reported on specific fucose-containing glycans present on extracellular vesicles (EVs) released by schistosomula, the early juvenile life stage of the schistosome, and the interaction of these EVs with the C-type lectin receptor Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN or CD209). EVs are membrane vesicles with a size range between 30–1,000 nm that play a role in intercellular and interspecies communication. Here, we studied the glycosylation of EVs released by the adult schistosome worms. Mass spectrometric analysis showed that GalNAc β 1–4GlcNAc (LacDiNAc or LDN) containing N-glycans were the dominant glycan type present on adult worm EVs. Using glycan-specific antibodies, we confirmed that EVs from adult worms were predominantly associated with LDN, while schistosomula EVs displayed a highly fucosylated glycan profile. In contrast to schistosomula EV that bind to DC-SIGN, adult worm EVs are recognized by macrophage galactose-type lectin (MGL or CD301), and not by DC-SIGN, on CLR expressing cell lines. The different glycosylation profiles of adult worm- and schistosomula-derived EVs match with the characteristic glycan profiles of the corresponding life stages and support their distinct roles in schistosome life-stage specific interactions with the host.

Introduction

Parasitic *Schistosoma* worms infect over 200 million people in Africa alone, and many millions more are infected in tropical areas of the Americas, Eastern Mediterranean, and Western Pacific¹. Infection takes place when cercariae, present in infected water, penetrate the skin and develop into egg producing adult worm pairs. Schistosomiasis is treatable with anti-helminthics but reinfection rates are high in endemic areas and there is no vaccine available yet. One of the reasons that *Schistosoma* infections are chronic if untreated and that effective immunity does not develop, is due to the immune modulatory strategies of the parasite that inhibit the generation of adequate protective immune responses². Studying the interaction of this ‘master regulator of the immune system’ with its host can lead to new treatment strategies against schistosome infections. Additionally, the identification of immune regulatory mechanisms utilized by schistosomes may help to identify new treatment opportunities for inflammatory disorders³.

During each of their life stages schistosomes employ various mechanisms to evade and control host immune responses during an infection. Most of the parasites’ immunomodulatory effects are attributed to excretory/secretory (ES) products, including glycosylated proteins and lipids. Via specific glycan motifs, these glycoconjugates are known to interact with a range of C-type lectin receptors (CLRs) mainly present on antigen presenting cells of the host. For example, the glycoprotein omega-1 derived from *S. mansoni* eggs enters monocyte-derived dendritic cells (moDCs) via binding of Gal β 1-4(Fuc α 1-3)GlcNAc (Lewis X, Le^x) motifs to the mannose receptor (MR)⁴. Schistosomula ES products have also been shown to interact with various other CLRs such as DCIR and DC-SIGN⁵, which bind to various fucosylated and mannosylated glycans. The schistosome glycan repertoire also includes GalNAc β 1-4GlcNAc (LacDiNAc or LDN)-motifs, which can be recognized by the macrophage galactose-type lectin (MGL)^{6,7}. Since schistosome glycosylation varies between the different life stages and their ES products, it is likely that differential glycosylation contributes to the differences observed in immune responses induced by schistosomula, adult worms, or eggs.

Recently, we found that the ES products of *S. mansoni* schistosomula contain extracellular vesicles (EVs) that play a role in pathogen–host interaction via uptake by dendritic cells⁸. EVs are lipid membrane vesicles released into the extracellular space by nearly all cells and organisms, including multicellular helminth parasites⁹. Generally, EVs are 30–1,000 nm in diameter with an average between 50–150 nm and can contain proteins, lipids, and nucleic acids, which can induce or affect responses by recipient cells. We showed that schistosomula EVs contain both protein- and lipid-linked glycans⁸, corresponding largely to the overall glycan profile of schistosomula⁶. Many of these glycans were highly fucosylated and a

relatively large proportion carried the Le^x trisaccharide, a well-known DC-SIGN ligand. We showed that these glycans mediated schistosomula EV uptake by moDCs mainly via interaction with DC-SIGN, leading to augmented cytokine release by the cells. A role for helminth EV-associated glycans in cellular uptake has also been described for *Fasciola hepatica*-derived EVs that displayed a glycosylation-dependent interaction with monocytes¹⁰. Similarly, roles for EV glycans in cancer biology are starting to become apparent^{11,12}, including their diagnostic potential¹³. However, studies on the role of EV glycosylation in parasite-host interaction and detailed studies of EV glycan structures remain limited^{14–16}.

It is known that the overall glycan repertoire of *S. mansoni* differs between larvae and adult worms⁶. To address whether glycosylation of schistosome-derived EVs is also life-stage dependent, we here elucidated the glycan structures of EVs released by *S. mansoni* adult worms using a mass spectrometry (MS) based approach. The differences in EV-associated glycans between adult worms and schistosomula were confirmed using glycan-targeted monoclonal antibodies (moAbs). Finally, we showed that EV surface glycans significantly influence the interaction of EVs with the MGL or DC-SIGN in CLR expressing cell lines. Our findings suggest that life stage-specific glycosylation of EVs by schistosomal larvae and adult worms influences the interaction of these EVs with host cells and subsequent cellular responses.

Materials and Methods

Parasite culture

Male and female adult worms from the Puerto Rican-strain of *S. mansoni* were obtained through liver perfusion of golden Syrian hamsters (HsdHan-Aura) 7 weeks post infection, in accordance with the Guide for the Care and Use of Laboratory Animals of the Institute for Laboratory Animal Research and have received approval from the university Ethical Review Board (Leiden University Medical Center, Leiden, The Netherlands). Collected worms were gently washed at least 5 times with 25–40 ml DMEM (high glucose with L-glutamine, Lonza, Basel, Switzerland) supplemented with Antibiotic Antimycotic Solution (Sigma-Aldrich, St. Louis, MO, USA) and 10 mM HEPES pH 7.4. Dead worms, residual hair or tissue and clot clots were removed. 200–400 worms were cultured in polystyrene culture flasks (75 cm²) (Corning, Sigma-Aldrich) in a concentration of 10 worms/ml. After 48 hours of culture at 37 °C 5% CO₂, worms were confirmed being viable by microscope and ES was subsequently collected in 50 ml tubes. The collected ES was centrifuged twice at 200 × *g* followed by two times at 500 × *g* (all 10 minutes, 4 °C, slow brake, in an SX4750A rotor in an Allegra X-15 R centrifuge)

(Beckman Coulter, Brea, CA, USA). The final $500 \times g$ supernatant was transferred to 15 ml tubes and centrifuged 30 minutes at $5,000 \times g$ (4°C , max brake) after which the $5,000 \times g$ supernatant was transferred to new tubes and stored at -80°C till further use. Cercariae were transformed to schistosomula and cultured as described previously⁸. The ES from 3 day cultured schistosomula was processed and stored similar as the adult worm ES using 15 ml tubes in all steps. As a control, supplemented DMEM without parasites was cultured and processed similarly. A summary of ES processing before EV isolation can be found in Figure 1 (top).

EV isolation and staining

Figure 1 (bottom) shows a schematic overview of the EV isolation steps described in more detail hereafter. The $5,000 \times g$ supernatants were thawed overnight at 4°C and transferred to polypropylene tubes (Beckman Coulter). Tubes were centrifuged for 65 minutes in an SW41 Ti rotor at 28,000 rpm (average $96,808 \times g$, k-factor 265) at 4°C in an XE90 centrifuge (Beckman Coulter). For one adult worm EV or schistosomula EV isolation, 60 ml (equal to material from 600 worms) or 20 ml (equal to material from 150,000 schistosomula) of $5,000 \times g$ supernatant was used, respectively. The EV-enriched pellets were resuspended and pooled in 20–60 μl PBS/0.2% BSA (made from 5% BSA in PBS, top 2/3 supernatant from >16 hours centrifuged at 28,000 rpm ($96,589 \times g$, k-factor 266) in an SW32 rotor) and transferred to a TLS-55 polypropylene tube. Diluent C was added to the resuspended EV pellet to obtain a total volume of 100 μl , to which 93 μl diluted PKH26 (Sigma–Aldrich) (1.5 μl in 100 μl Diluent C) was added. After 3 minutes, the staining reaction was quenched by the addition of 100 μl RPMI/10% EV depleted




Figure 1. Schematic overview of ES processing and EV isolation

Summary of the processing of adult worm and schistosomula ES (top) and subsequent EV isolation (bottom). *additional details on EV isolation for glycan release and western blotting can be found in the corresponding methods sections. ES, excretory/secretory products; sup, supernatant; min, minutes; h, hours

FCS (top 2/3 supernatant from RPMI/30% FCS centrifuged >16 hours at 28,000 rpm in SW32 rotor). Stained pellets (293 μ l) were gently mixed with 660 μ l 60% iodixanol (Optiprep, Axis-Shield PoC AS, Oslo, Norway) and a gradient was built on top with 220 μ l 40%, 220 μ l 30%, and 720 μ l 10% iodixanol. Gradients were centrifuged in an Optima TLX centrifuge (Beckman Coulter) for 2 hours at 50,000 rpm (average $166,180 \times g$, k-factor 60) (slow acceleration and deceleration) and 4 °C in a TLS-55 rotor. Fractions were collected from the gradient from top to bottom by pipetting one time 500 μ l (F8) followed by six times 100 μ l (F7-2) and a remaining 1 ml bottom fraction (F1). The refractive index (RI) of the fractions were measured with a CETI refractometer (Medline Scientific, Chalgrove, UK) (15 μ l per fraction) and densities were calculated with the formula $(3,35 \times (\text{RI}) - 3,4665)$. F6-3 were pooled in an SW41 tube and topped up with cold PBS. The tube was covered with parafilm and decanted for 10 times after which the tube was spun at 39,000 rpm (average $187,813 \times g$, k-factor 136) in an SW41 Ti rotor for 65 minutes (4 °C). The purified EV pellet was resuspended in 275 μ l PBS and aliquots were stored at -80 °C. Medium control was processed similarly as control for unbound dye.

Protein concentration of a thawed aliquot of purified EV was measured according to the manufacturers protocol for microBCA (Pierce, Thermo Fisher Scientific, Waltham, MA, USA). For nanoparticle tracking analysis (NTA), aliquots were thawed from -80 °C and 100 times diluted in PBS directly before NTA measurement. Each sample was recorded three times 30 seconds on camera level 12, 14, and 16 on a NanoSight NS500 (Malvern Panalytical, Malvern, UK) equipped with an sCMOS camera. The analysis and average particle concentration calculation was performed as previously described⁸. All relevant data of our experiments have been submitted to the EV-TRACK knowledgebase (EV-TRACK ID: EV220409)¹⁷.

Cryo electron microscopy

EVs were purified on a density gradient as described above. The EV containing fractions with a density between 1.21-1.07 g/ml were pooled (total volume of 580 μ l) and washed with PBS on a 0.5 ml 10 kDa centrifugal filter (Amicon, Merck KGaA, Darmstadt, Germany) as described¹⁸. The sample (3 μ l) was subsequently applied on a 300 mesh EM grid (Quantifoil R2/2, Jena, Germany) that was previously glow-discharged (2 minutes in 0.2 mbar air using a EMITECH K950X with glow discharger unit) and vitrified using an EMGP (Leica, Wetzlar, Germany) at room temperature and 100% humidity. Excess sample was removed by blotting once for 1 second with filter paper (Whatman #1). The blotted grid was plunged into liquid ethane (-183 °C). After vitrification, the grid was stored under liquid nitrogen until further use. The grid was mounted in a Gatan 626 cryo-holder for cryo-EM imaging. Cryo-EM imaging was performed on a Tecnai 12 electron microscope

(FEI Company, Eindhoven, The Netherlands) operated at 120 kV. Images were recorded on a 4k×4k Eagle camera (FEI Company) at 18,000 × magnification (pixel size 1.2 nm) between 5 and 10 µm under focus.

Glycan release

Iodixanol purified EVs from 600 adult worms were used for the release of total N-glycans as previously described⁶. Briefly, lyophilized EVs were sonicated and denatured before 24 hours N-glycosidase (PNGase) F (4 U/100 µl, Roche Diagnostics, Almere, The Netherlands) treatment. Released N-glycans were isolated and purified using reversed phase (RP) C18-cartridges (JT Baker, Phillipsburg, NJ, USA) loaded with the PNGase F treated sample followed by loading the flow through on carbon cartridges (Supelclean ENVI-carb SPE, Sigma-Aldrich) as described¹⁹. Additionally, intact purified EVs without prior denaturation were treated with PNGase F for 24 hours at 37 °C, after which the EVs were resuspended with PBS in a TLS-55 tube and spun for 65 min (4 °C) at 42,000 rpm (average 117,553 × g, k-factor 87) in an Optima TLX centrifuge. N-glycans released in this way from the EV surface were isolated from the supernatant and the EV pellet was resuspended and treated as above to obtain the remaining EV associated glycans that were not released by PNGase F. To obtain glycolipid derived glycans, purified as well as enriched adult worm EVs were treated with endo-glycoceramidase as described previously⁸. All isolated glycans were labelled with 2-aminobenzoic acid as described¹⁹.

Glycan analysis

Isolated glycans were analyzed using Matrix Assisted Laser Desorption/ Ionisation – Time of flight mass spectrometry (MALDI-TOF-MS) using a Bruker Daltonics UltrafleXtreme® mass spectrometer equipped with a 1 kHz Smartbeam II laser and controlled by the software FlexControl 3.4 Build 119, as previously reported¹⁹. 2-AA labelled glycans solubilized in MQ were mixed onto a 384-well polished steel target plate with 2,5-dihydroxybenzoic acid (DHB) matrix (#8201346, Bruker Daltonics, 20 mg/ml in 30% ACN) while products of exoglycosidase digestions were directly eluted onto the plate in 50% ACN, 0.1% TFA mixed with DHB (10 mg/ml) at the end of the enzyme removal with C18 Millipore® Zip-Tips. All spectra were obtained in the negative-ion reflectron mode using Bruker® peptide calibration mix (#8206195, Bruker Daltonics) for external calibration. Spectra were obtained over a mass window of m/z 700 – 3500 with ion suppression below m/z 700 for a minimum of 20,000 shots (2000 Hz) obtained by manual selection of “sweet spots”. The software FlexAnalysis (Version 3.4 Build 50) was used for data processing including smoothing of the spectra (Savitzky Golay algorithm, peak

width: m/z 0.06, 1 cycle), baseline subtraction (Tophat algorithm) and manual peak picking. Peaks with a signal-to-noise ratio below 3 were excluded as well as known non-glycan peaks or contaminating glucose polymers. Deprotonated masses of the selected peaks were assigned using the GlycoPeakfinder® tool of the free software GlycoWorkBench (Version 3, 29 June 2007)²⁰. The 2-AA label was taken into account as a fixed reducing-end modification and possible glycan composition was set up based on available schistosome glycosylation data in the literature⁶. A deviation of 300 ppm was allowed for initial assignment of compositions. Spectral assignments were aided by additional MS/MS measurements, exoglycosidase sequencing, and available published structural data⁶. MS/MS was performed for structural elucidation via fragmentation ion analysis by MALDI-TOF/TOF on selected ions using the UltrafleXtreme® mass spectrometer in negative-ion mode. Confirmation of structures was also aided by treatments of N-glycans with β -N-acetylglucosaminidase from *Streptococcus pneumoniae* and β -N-acetylhexosaminidase from *Streptomyces plicatus* (New England Biolabs, Ipswich, MA, USA; P744, P721, respectively). Enzymatic digestions were performed by digesting 1–2 μ L of 2-AA labelled glycan overnight at 37 °C in recommended buffer in 10 μ L total reaction volumes.

Western and lectin blotting

EV-enriched pellets from adult worm ES (per gradient from 300–600 worms) or schistosomula ES (per gradient from 110,000–220,000 schistosomula) were resuspended in 73 μ L PBS/0.2% BSA, transferred to TLS-55 tubes, and gently mixed with 440 μ L 60% iodixanol. The gradient was built by carefully loading 220 μ L 40%, 220 μ L 30%, and 792 μ L 10% iodixanol on top and spun as described above. After centrifugation, 12 equal fractions of 145 μ L were collected from top to bottom, 15 μ L was used for determining the refractive index, and 125 μ L was directly mixed with 42 μ L 4 $\times$ non-reducing sample buffer (0.2 M TrisHCl pH 6.8, 8% SDS, 40% glycerol, and Bromophenol blue). In addition, the 96,589 $\times$ g EV-depleted supernatant of the ES was concentrated in 10 kDa filter tubes (Amicon) to 300.9 μ L to which 100.2 μ L 4 $\times$ non-reducing sample buffer was added. This mix was 5 times diluted in sample buffer to load an equal end volume compared to all the fractions of one gradient. All samples were heated at 98 °C for 3 minutes and stored at –20 °C till SDS-PAGE.

15 μ L of sample or 1.5 μ L of marker (PageRuler Plus, Thermo Fisher Scientific) was run into a 12.5% gel, blotted onto PVDF membranes and blocked with blocking buffer consisting of PBS supplemented with 0.1% Tween-20 and 0.2% gelatin from cold water fish skin (Sigma-Aldrich). Blots were incubated overnight with antibodies (1:200–1:2000) in blocking buffer. Antibodies used included: TSP2–2D6

(kind gift from prof. Alex Loukas, James Cook University, Australia) and monoclonal antibodies generated in house at LUMC²¹: 100-4G11²², 114-4D12, 128-1E7, 258-3E3, 273-3F2, 290-2E6, and 291-5D5. Bands were visualized with chemiluminescence substrate (SuperSignal West Pico PLUS, Thermo Fisher Scientific) in an Alliance Q9 (UVITEC, Cambridge, UK) and analysed with Fiji/ImageJ²³.

For the lectin blots, 260 µl of EV enriched pellets from 1200 adult worms was split equally (130 µl) and incubated with or without PNGase F (4 U/100 µl) for 24 hours at 37 °C. EVs were subsequently purified with an iodixanol gradient and fractions 4-7 (1.08-1.20 g/ml) were pooled and washed as described above. Final pellets were resuspended in 70 µl PBS and mixed with 2× non-reducing sample buffer, heated, and stored as described. Similar SDS-PAGE and blotting was performed as above. Blocking buffer for the lectin blots consisted of TBS supplemented with 5% BSA and 0.1% Tween-20. Blots were blocked overnight and subsequently incubated for 1 hour with 5 µg/mL biotinylated SBA (*Glycine max* (soybean) agglutinin) or DBA (*Dolichos biflorus* agglutinin) (Vector laboratories, Burlingame, CA, USA). Visualization was done as described above after 30 minutes of Streptavidin poly-HRP (Sanquin, Amsterdam, The Netherlands) incubation and several washing steps.

PNGase F treatment of EVs for cell experiments

EV-enriched pellets, obtained as described above from 120 ml adult worm (material from 1200 worms) or 40 ml schistosomula (from 300,000 schistosomula) 5,000 × g supernatant, were resuspended in a total volume of 150 µl or 100 µl PBS with 0.2% BSA (as above), respectively. Pellets were then split in two separate Eppendorf tubes and 4 µl PNGase F (4 U) was added to one of these two tubes. All samples were incubated for 20 hours at 37 °C after which the EV were stained with PHK26 and isolated via a iodixanol density gradient as described above. The final purified EV pellets were resuspended in 175 µl PBS and stored at -80 °C till further use.

C-type lectin receptor cell lines

CHO and CHO-MGL (kind gift from dr. ing. S.J. van Vliet²⁴ cells were maintained in RPMI supplemented with 10% FCS, L-glutamine (20 µM), penicillin (100 U/ml), and streptomycin (100 U/ml). K562 and K562-DC-SIGN cells (kind gift from prof. dr. C.G. Figdor²⁵ were maintained in DMEM with 10% FCS, L-glutamine, pyruvate (20 µM), penicillin, and streptomycin. Geneticin (0.6 mg/mL) (G418, Roche Diagnostics) was added to the CHO-MGL and K562-DC-SIGN cultures to select for cells with the CLR expressing vector. Cells (400,000/ml) rested for 2 hours (37 °C, 5% CO₂) after harvest before addition of PKH26 labelled EVs or dye control with or without 30 minutes EGTA (10 mM) pre-incubation. After 18

hours incubation, cells were placed on ice, harvested, stained with Aqua live/dead staining (Invitrogen, Thermo Fisher Scientific), and measured on a FACSCanto II (BD Bioscience, Franklin Lakes, NJ, USA). Receptor expression was measured by staining cells with α CD209-V450 (clone DCN46, BD Biosciences), α CD301-APC (clone H037G3, Biolegend, San Diego, CA, USA), α Fc γ RIIb-binding inhibitor (eBioscience, Invitrogen, Thermo Fisher Scientific), and 7AAD viability dye (eBioscience).

Data was statistically analyzed in GraphPad Prism 8.0 (GraphPad Software Inc., La Jolla, CA, USA) using a repeated measure One-way ANOVA with Dunnett's Multiple Comparison Test. *P* values <0.05 were considered significant.

Results

Characterization of adult worm EVs by cryo-EM and NTA

S. mansoni adult worm EVs were isolated from ES collected following a 48 hour culture of adult worms using sequential (ultra)centrifugation and density gradient purification to separate EVs from non-EV particles. EV preparations were visualized by cryo-EM and showed the presence of 30–180 nm vesicles (Figure 2A). Part of these EVs had small structures extruding from their surface (Figure 2A, arrows and bottom panel). NTA of the adult worm EVs showed a size-range between 30 and 250 nm with the majority of the EVs to be around 90 nm in size (Figure 2B). The small peaks of particles observed in the medium control (similarly processed culture medium without parasites) and in PBS alone, were considered background noise of the NTA. The average number of particles measured was equal to 6.85×10^9 per 100 adult worms with an average of 4.89 μ g protein from EVs of 100 adult worms.

EV surface contains glycan motifs prevalent in adult worms

To study glycosylation of adult worm EVs, the isolated N-glycans and glycolipid-derived glycans were analyzed by mass spectrometry. Glycan structures were assigned to each of the observed molecular ions using the previously published whole adult worm glycan profiles as reference library⁶. The N-glycan composition of the adult worm EVs (Figure 3A) revealed a similar complex glycan profile as described for 6-week old adult worms⁶. The two major ion peaks in the spectrum represented core(α 6)-fucosylated di-antennary structures containing the LDN motif on either one or both antennae. Less abundant N-glycans observed in the spectrum were oligomannosidic structures (3–9 mannoses), glycans with one or two antennae consisting of Gal β 1–4GlcNAc (LacNAc, LN), or an LN and LDN combination, and two minor peaks with structures containing an LN and





Figure 2. Isolated EVs from *Schistosoma* adult worms visualized by cryo-EM and measured by NTA

Purified EVs were visualized by cryo-EM (A) showing surface structures (corona) on part of the EVs (arrows). The bottom panel shows two individual EVs with a copy in which the surface structure is drawn in blue. White scale bars are 500 nm, black scale bars are 100 nm. NTA was performed on purified adult worm EVs from eight biological replicates of which the average is shown (black line) with SEM (grey area) (B). In addition, four medium controls (orange) and four samples PBS (background) in which the EVs were resuspended (blue) are shown.

Le^x or two Le^x motifs. Each of these N-glycans were previously confirmed to be present in whole adult worm extracts⁶. In all repeated analyses, glycolipids were not detectable in the adult worm EVs (data not shown).



Glycans present on the EV surface can form ligands for host lectins that play a role in the activation and modulation of immune responses^{4,22,26}. To identify these surface glycans, intact purified adult worm EVs were first treated with PNGase F to release and collect EV surface N-glycans. The remaining 'shaved' EVs were re-pelleted, disrupted by sonication and denaturing, and then again treated with PNGase F to release the N-glycans present on the inside of the shaved EVs. The most abundant N-glycans at the EV surface (Figure 3B) were the same LDN-containing structures that were most abundant in the total EV N-glycan profile. The minor peaks observed also represented similar structures with LN or LN-LDN antennae as observed in the total spectrum. In the shaved EV

← **Figure 3. Most relative abundant complex N-glycans on adult worm EVs contain LDN-motif**

N-glycans released by PNGase F of total (A), intact ('surface' N-glycans accessible to the enzyme) (B), and PNGase F treated ('shaved', N-glycans on surface or inside EV that PNGase F cannot access) (C) adult worm EVs were measured by MALDI-TOF-MS. To confirm the presence of GalNAc β 1-4GlcNAc (LDN) antennae in glycans released from EV surface in B, AA-labeled N-glycans were treated with either β -N-acetylglucosaminidase, β -hexosaminidase, or both. β -N-acetylglucosaminidase removes GlcNAc residues only after they become accessible by β -hexosaminidase digestion to remove the terminal β -linked GalNAc residues. Peaks are labelled with their monoisotopic masses. The structural assignments are putative and were deduced from the masses (which includes the 2-AA label) and previously published data⁶. These are representative spectra for three biological replicates. Green circle, mannose; yellow circle, galactose; blue square, N-acetylglucosamine; yellow square, N-acetylgalactosamine; red triangle, fucose. *, signals corresponding to hexose oligomer of unknown origin; #, non-glycan signals

however, oligomannosidic structures (3–9 mannoses) were the most abundant, and complex-type N-glycans were not detected (Figure 3C). The occurrence of a single LDN antenna rather than two separate GlcNAc terminating branches in the N-glycan species observed at m/z 1582.6, and occurrence of two LDN antenna in the m/z 1988.7 structure, were confirmed by treatments with N-acetylglucosaminidase and N-acetylhexosaminidase (Figure 3D) and by MS/MS fragmentation analysis (Supplementary Figure S1). These results indicate that *S. mansoni* adult worm EVs expose N-glycans with one or two terminal LDN motifs.

Difference in EV-associated glycoconjugates between adult worms and schistosomula

To confirm the glycan data obtained by mass spectrometry (Figure 3 and Kuipers *et al.*⁸), and make a direct comparison with schistosomula EVs we investigated glycosylation of both adult worm and schistosomula EVs by western blotting. Monoclonal antibodies (mAbs) directed against various glycan motifs including LDN, the unsubstituted tri-mannosyl core motif, and fucosylated (F)-GlcNAc (Supplementary Figure S2) were used to visualize glycoproteins with these motifs in their N-glycans, as well as in O-glycans possibly present but undetected by our MS approach. An overview of the detected glycans in EVs and EV-depleted supernatant of both life stages (as analyzed in Supplementary Figure S2A) is provided in Table 1. The presence of the EV marker Tetraspanin-2 (TSP2) confirmed that the majority of the EVs from adult worms and schistosomula were present in

fractions with a density of iodixanol between 1.07 and 1.16 g/ml (Figure 4). For the adult worms, minute amounts of TSP2 were also detected in the bottom fraction and top fractions and in the EV-depleted supernatant.

The most abundant glycan motifs detected in the adult worm EVs were LDN, the tri-mannosyl motif, and LDN with a GlcNAc-linked fucose (GalNAc β 1-4(Fuc α 1-3)GlcNAc, LDN-F) (Table 1). These same motifs were also detected in the EV-depleted supernatant, however, with a different band pattern (Supplementary Figure S2B), suggesting that the EVs and EV-depleted supernatant contain different glycoprotein subsets. Mabs targeting fucosylated GalNAc, such as Fuc α 1-3GalNAc β 1-4(Fuc α 1-3)GlcNAc (F-LDN-F), or fucosylated GlcNAc (Fuc α 1-3GlcNAc, F-GlcNAc) were not reactive in western blots of adult worm EV samples. The diverse glycosylation of schistosomula EVs, previously characterized by mass spectrometry⁸, was illustrated using western blotting by the substantial recognition of F-LDN, LDN-F, and F-GlcNAc motifs (Table 1). In accordance with the previous findings, unsubstituted LDN was not detected in schistosomula EV. Interestingly, the tri-mannosyl was abundantly detected in the schistosomula EV-depleted supernatant (Supplementary Figure S2B). Other glycan specific band patterns in the EV-depleted supernatant were also distinct from the patterns observed in the EV fractions. Together, these findings suggest




Figure 4. Tetraspanin-2 containing EV fractions in iodixanol gradient.

EV enriched pellets were floated upwards into iodixanol density gradients. Twelve equal fractions were obtained, mixed with sample buffer and loaded on an SDS-PAGE gel followed by western blot targeting *Schistosoma* Tetraspanin-2 (TSP2). EV depl. sup = EV depleted supernatant (100,000 $\times$ g supernatant that was concentrated to equal volume of the full density gradient).

that EVs contain glycoproteins distinct from those in non-EV ES products. Moreover, the western blot data confirm along with the mass spectrometry data that schistosomula and adult worm EVs are differentially glycosylated, in line with the overall differential glycosylation of these schistosome life stages⁶.

Adult worm EVs interact with MGL receptor

Previously, we found that *S. mansoni* schistosomula EVs interact with DC-SIGN, but not with MR or DCIR, which was in line with the clear presence of DC-SIGN ligands on the schistosomula EV surface⁸. Since the most abundant N-glycans on the surface of the adult worm EVs contained LDN (Figure 3C), we reasoned that adult worm EV could bind to MGL rather than DC-SIGN. MGL is a CLR expressed on monocyte-derived DCs and macrophages, capable of binding LDN- and GalNAc-containing glycoconjugates present in helminths and tumors²⁷.

Table 1. Glycan motifs in EV or EV-depleted supernatant from adult worms and schistosomula detected with western Blot. – : not detected; + : 1–50,000; ++ : 50,000–200,000; +++ : >200,000 area under the curve measured in ImageJ. Data based on blots in Supplementary Figure 2B. LDN, GalNAcβ1–4GlcNAcβ1–; LDN-F, GalNAcβ1–4(Fucα1–3)GlcNAcβ1–; F-GlcNAc, Fucα1–3GlcNAcβ1–; F-LDN, Fucα1–3GalNAcβ1–4GlcNAcβ1–; F-LDN-F, Fucα1–3GalNAcβ1–4(Fucα1–3)GlcNAcβ1–; DF-GlcNAc, Fucα1–2Fucα1–3GlcNAcβ1–; TF-GlcNAc, Fucα1–2Fucα1–3GlcNAcβ1–


	 LDN	 tri-manno-syl core	 LDN-F	 F-LDN-F	 F-GlcNAc	 TF-GlcNAc	 F-LDN-F
Adult worm EV	+	+	++	–	–	–	–
Adult worm EV-depleted supernatant	+	+	+	–	–	–	–
Schistosomula EV	–	–	+	++	++	+++	++
Schistosomula EV-depleted supernatant	–	++	+	+	+	+	+++

Indeed, flow cytometric measurements of cell lines overexpressing the MGL or DC-SIGN receptor (Supplementary Figure S3) showed a significant interaction of MGL with fluorescently labelled adult worm EVs, while these EVs did not interact with DC-SIGN expressing cells (Figure 5A). The opposite was observed for the schistosomula EVs, which were strongly interacting with DC-SIGN but less with MGL (Figure 5B). These EV-CLR interactions were confirmed to be glycan-dependent, as the pre-incubation of EGTA disabling the Ca^{2+} dependent glycan binding domain of CLR, reduced the binding or uptake of EVs.

Since we observed that the LDN-containing N-glycans on the surface of the adult worm EVs could be removed by PNGase F (Figure 3D), we studied the effect of PNGase F treatment of EVs on MGL-dependent binding. Surprisingly, PNGase F treatment had no significant effect on adult worm EVs binding or uptake by the CLR expressing cells (Figure 5C). Similarly, PNGase F treatment did not affect schistosomula EVs binding to DC-SIGN (Figure 5D), which we attributed earlier to the presence of additional and abundant DC-SIGN ligands within the schistosomula EV-associated glycolipids⁸. We did not detect any glycolipids in the adult worm EVs, however, to possibly explain the MGL affinity remaining after removal of LDN-containing N-glycans. Therefore, we investigated by lectin blotting whether PNGase F treatment resulted in complete LDN removal as expected (Figure 3C) and whether the adult worm EVs might also contain other MGL ligands such as Tn antigens. The Tn antigen is an O-linked α -GalNAc residue often occurring in mucin domains and a known MGL ligand produced by various organisms, including mammals and helminths²⁴. Lectin blotting with SBA, which recognizes both α -GalNAc (as in Tn) and β -GalNAc (as in LDN), showed that PNGase F treatment did indeed affect N-glycan contained LDN reactivity. The band around

→ **Figure 5. Interaction *Schistosoma* EVs with MGL or DC-SIGN expressing cell lines suggest multiple MGL ligands on adult worm EVs**

Fluorescently labelled EVs from adult worms (A) or schistosomula (B) or dye (PKH) control were incubated with MGL or DC-SIGN expressing cell lines and measured for fluorescence by flow cytometry. The geometric mean fluorescent intensity (geoMFI) of similar cell lines without CLR expressing vector incubated with EVs (control) was subtracted from the geoMFI of the cells with the CLR. Similar experiment was performed with EVs treated with PNGase F before density gradient isolation (C-D). Adult worm EVs treated with or without PNGase F were loaded on SDS-PAGE followed by western blot for detection of LDN (SBA lectin) and Tn antigen (DBA lectin) (E). EV concentrations are given in EV/ml. Data from 3-4 independent experiments. Mean $\pm$ SEM * $p < 0.05$, **** $p < 0.0001$, using repeated measures ANOVA with Dunnett's Multiple Comparison Test compared to PKH control.



23 kDa was absent in the PNGase F treated EV lane, and the band at ~30 kDa disappeared while a new band showed at ~26 kDa (Figure 5E), likely due to removal of N-glycans resulting in a mass shift. The remaining SBA binding after PNGase F treatment suggests that other SBA ligands than N-glycan LDN, such as O-linked glycans with the LDN motive or the Tn antigen are present. Application of DBA, which binds only α -GalNAc, confirmed that glycoproteins of adult worm EVs indeed contain Tn antigen, and that these are not affected by PNGase F treatment. These findings suggest that the interaction of PNGase F treated, N-glycan shaved, adult worm EVs with MGL are most likely due to the presence of O-linked GalNAc residues exposed on the EVs.

Discussion

Helminth parasites, including *S. mansoni*, release EVs that can interact with host cells. There are multiple publications reporting about the proteome and transcriptome of adult schistosoma^{28–31}. However, the glycans associated with these worm EVs remain largely undescribed and their role has been almost completely unexplored so far^{8,32}. Here we found that EV released by adult worms contained complex N-glycans with LDN motifs, which were almost exclusively present on the EV surface. The observed EV-glycan profile corresponds with the glycan profile of entire adult worms⁶. This similarity between the overall glycan profile of a life stage and the glycan profile of their released EVs has been previously observed for schistosoma as well⁸. This indicates that the previously observed differences in overall N-glycan profile between the two life stages⁶ are reflected in their released EVs (Figure 3A and Kuipers *et al.*⁸), where adult worm EV N-glycans mainly contain LDN, but not highly fucosylated glycans as observed for schistosoma EVs. This was confirmed by both mass spectrometry (Figure 3) and glycan-targeting antibodies in a western blot analysis (Table 1, Supplementary Figure S2). In contrast to a recent publication on *S. mansoni* adult worm EVs that were analyzed by lectin microarrays³², we did not detect sialylated host-derived glycans in our EV preparations (Figure 3). We did not use FCS in worm culture medium and applied multiple washing steps before EV analysis to exclude the presence of host material. Helminths, such as *S. mansoni*, lack the molecular machinery for the biosynthesis of sialylated glycans³³. Although our data shows that schistosomes in an *ex vivo* culture do not release EVs with sialylated glycan motifs, it could be possible that host glycoproteins are incorporated into schistosoma EVs *in vivo*, or that host-derived sialic acids get incorporated into schistosoma products otherwise³⁴.

The majority of the EV-associated glycoprotein glycans we detected have previously been reported to be present in whole adult worm extracts. We could,

however, not detect glycolipids known to be abundantly present in adult worms⁶ in the purified worm EVs. In contrast, glycolipids are ample and diverse in the case of schistosomula-derived EVs⁸. Furthermore, the unique long filamentous ‘hair-like’ structures previously observed on the surface of schistosomula EVs⁸ were not present on adult worm EVs (Figure 2A). These observations could suggest a difference between schistosomula and adult worms in cellular source and pathways from which the EVs derive. There is evidence that schistosomula EVs are released from their pre-acetabular glands³⁵, although they may also origin from the cercarial glycocalyx, as their long surface filaments resemble the glycocalyx morphology³⁶. The source of adult worm EVs is largely unknown but we suggest that the adult worm gut and tegument are likely candidates as a high abundance of LDN structures has been reported for both locations using lectin staining³⁷. In addition, the EV marker TSP2 has been found abundantly on the adult worm tegument³⁸. Both tegument and gut-derived EVs have been observed or suggested to occur for other helminths³⁹, but the exact adult *S. mansoni* worm EV source or sources remain(s) to be elucidated. The corona structure on adult worm EVs (Figure 2A) appears to be a unique feature. The EV (protein) corona gained more interest just recently⁴⁰ and to our current knowledge the structures observed on the adult worm EV surface have not been imaged/reported as such on the surface of naturally released mammalian EVs in the absence of blood plasma. Since we did not detect host-derived sialic acids in our measurements, it is also unlikely that the worm EV corona observed consists of host material, yet the exact composition remains to be elucidated. These coronas do resemble the surface structures seen on EVs from transfected mammalian cells enriched in nematode or viral membrane proteins⁴¹. Furthermore, coated EVs have been reported for other helminths⁴², fungi⁴³, and bacteria^{44,45}. It is therefore tempting to suggest that these membrane structures are a hallmark of pathogen-derived EVs and may be involved in pathogen-host interaction.

The finding that adult worm EVs interacted more significantly with MGL compared to DC-SIGN, while for the schistosomula EV the opposite was found (Figure 5) indicates that the glycosylation of *S. mansoni* EVs drives their interaction with host cells. Both receptors are selectively present on DCs and macrophages but rarely coincide on the same cell *in vivo* and have only been found together on some cells in the small intestine⁷, suggesting distinct immunological functions. DC-SIGN can bind glycoconjugates containing either mannose or fucose structures which, in specific molecular context and with additional TLR activation, can promote Th1 and Th2 responses, respectively⁴⁶. For *Schistosoma* larvae, it has been suggested that their fucosylated glycolipids are recognized by DCs in the skin⁴⁷. These DCs react to the parasite with pro-inflammatory responses, yet the

DC-SIGN activation induces an increase of anti-inflammatory cytokine IL-10. This increase in IL-10 prevents the generation of full adaptive responses which allows successful reinfection of the host⁴⁸. Similar responses have been observed in moDC for the DC-SIGN binding schistosomula EVs that contain ample fucosylated glycolipids⁸. Glycolipids are insensitive to PNGase F treatment and we indeed still observed schistosomula EV-DC-SIGN interaction with the CLR-expressing cell lines after enzymatically removing the N-glycans (Figure 5D), similar to what we previously found for moDCs⁸.

Although mouse MGL1 can recognize Le^x motifs, the human MGL cannot⁷, and the observed interaction of schistosomula EVs with the human MGL in our experiments might be through the interaction of terminal GalNAc residues of the LDN-F epitopes present in schistosomula EV glycans (Table 1)⁷. The binding capacity of schistosomula EVs to MGL is limited, in contrast to the interaction of the adult worm EVs with this receptor (Figure 5). This finding is corroborated by the high abundance in adult worm EV of LDN motifs and the Tn antigen (Figure 5E), which are the two major ligands of the MGL²⁷. The MGL is mainly associated with tolerogenic DCs and macrophages and MGL stimulation by the Tn antigen strongly increases IL-10 release⁴⁹. MGL is superior to DC-SIGN in the ability to generate IL-10 producing regulatory T cells after DCs stimulation⁵⁰ and is mainly investigated for its role in tumor immunology⁵¹. Tumor cells are known to have altered glycosylation and the presence of the Tn antigen has been correlated to poor clinical outcome⁵². Although it has been shown that helminths such as *S. mansoni* stimulate the generation of regulatory cells⁵³, an exact role for the MGL during helminth infection has not been elucidated so far²⁷. We therefore hypothesize that the adult worms release EVs to stimulate immune tolerance via interaction with the MGL. For example, human monocytes increase their MGL expression in the presence of IL-4⁵⁴, a Th2 cytokine that accumulates in the granuloma induced by eggs trapped in the liver, which in turn links to the increased presence of alternatively activated macrophages (M2). It is therefore possible that adult worm EVs contribute to protecting the host from egg-derived toxins via MGL-induced tolerance⁵⁵. Interestingly, also schistosome egg-derived glycoprotein kappa-5 contains the LDN motif, as well as LDN-F. However, in addition to MGL, kappa-5 has been shown to interact with DC-SIGN and MR on the basis of the fucosylated LDN variant⁵⁶. Another observation for possible adult worm EV-induced tolerance comes from vaccination studies. Whereas recombinant *Schistosoma* TSP2 is a potential vaccine candidate against schistosomiasis⁵⁷, initial vaccine studies with complete adult worm EVs showed no clear protection thus far⁵⁸. This low efficacy of TSP2-containing worm EVs might be due to tolerogenic properties induced by

EV glycosylation.

There are profound differences between the *Schistosoma* life stages. The schistosomulum has to find a way via the skin to the lungs and fight off the first line of defense of the host immune system while establishing infection and maturing into adult worms. Once developed into adult worms, the parasites reside in the veins near the liver and the gut where they need to establish a chronic infection and stay alive for years if untreated. Hence, the adult worms utilize different strategies than the larvae to evade or limit host responses. These differences are not only reflected in the morphology and glycosylation of the adult worms and schistosomula themselves, but also their released EVs. Furthermore, we found that glycosylation patterns differ between EVs and EV-depleted ES (Table 1). This suggests that EVs from these parasites have a distinct contribution to infection and survival within their host. Studying the interactions of schistosome EVs with host CLRs not only increases our understanding of the roles of CLRs during helminth infections, it can also tell us how we could target these CLRs to either generate immune activation to fight infections and tumors or to induce immunotolerance to dampen unwanted inflammations.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contributions

MEK performed the majority of the experiments. DLN and AvD performed the glycan characterizations and assisted with the analysis of the spectra. LM contributed to the CLR experiments. EB and RIK generated the cryo-EM images. MEK, ENMH, HHS and CHH conceived the project and contributed to the design of experiments and interpretation of the results. MEK and CHH wrote the manuscript. All authors revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) Graduate School Program[022.006.010] (to MEK) and the Dutch Lung Foundation AWWA Consortium [5.1.15.015] (to HHS).

Acknowledgments

The authors would like to thank Jan de Best and the rest of the life-cycle team for maintaining the availability of the parasites, Professor Alex Loukas from James Cook

University, Queensland (Australia), for providing the TSP-2-targeting antibodies, Sjaak van Voorden and the rest of the Medical Microbiology department (LUMC) for using their refractometer, Uvitec Alliance, ultracentrifuges, and rotors, and Dr. ing. Sandra van Vliet from the AmsterdamUMC and Professor Carl Figdor from RadboudUMC, Nijmegen (The Netherlands), for providing the CLR-expressing cell lines.

References


- Colley, D. G., Bustinduy, A. L., Secor, W. E. & King, C. H. Human schistosomiasis. *The Lancet* **383**, 2253–2264 (2014).
- Jenkins, S. J., Hewitson, J. P., Jenkins, G. R. & Mountford, A. P. Modulation of the host's immune response by schistosome larvae. *Parasite Immunol* (2005).
- Maizels, R. M., Smits, H. H. & McSorley, H. J. Modulation of Host Immunity by Helminths: The Expanding Repertoire of Parasite Effector Molecules. *Immunity* **49**, 801–818 (2018).
- Everts, B. *et al.* Schistosome-derived omega-1 drives Th2 polarization by suppressing protein synthesis following internalization by the mannose receptor. *J Exp Med* **209**, 1753–67, S1 (2012).
- Bloem, K. *et al.* DCIR interacts with ligands from both endogenous and pathogenic origin. *Immunol Lett* **158**, 33–41 (2014).
- Smit, C. H. *et al.* Glycomic Analysis of Life Stages of the Human Parasite *Schistosoma mansoni* Reveals Developmental Expression Profiles of Functional and Antigenic Glycan Motifs. *Mol Cell Proteomics* **14**, 1750–1769 (2015).
- van Vliet, S. J., Saeland, E. & van Kooyk, Y. Sweet preferences of MGL: carbohydrate specificity and function. *Trends in Immunology* **29**, 83–90 (2008).
- Kuipers, M. E. *et al.* DC-SIGN mediated internalisation of glycosylated extracellular vesicles from *Schistosoma mansoni* increases activation of monocyte-derived dendritic cells. *J Extracell Vesicles* **9**, 1753420 (2020).
- Sánchez-López, C. M., Trelis, M., Bernal, D. & Marcilla, A. Overview of the interaction of helminth extracellular vesicles with the host and their potential functions and biological applications. *Molecular Immunology* **134**, 228–235 (2021).
- de la Torre-Escudero, E. *et al.* Surface molecules of extracellular vesicles secreted by the helminth pathogen *Fasciola hepatica* direct their internalisation by host cells. *PLoS Negl Trop Dis* **13**, e0007087 (2019).
- Dusoswa, S. A. *et al.* Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells. *J Extracell Vesicles* **8**, 1648995 (2019).
- Nishida-Aoki, N., Tominaga, N., Kosaka, N. & Ochiya, T. Altered biodistribution of deglycosylated extracellular vesicles through enhanced cellular uptake. *Journal of Extracellular Vesicles* **9**, (2020).
- Martins, Á. M., Ramos, C. C., Freitas, D. & Reis, C. A. Glycosylation of Cancer Extracellular Vesicles: Capture Strategies, Functional Roles and Potential Clinical Applications. *Cells* **10**, (2021).
- Kuipers, M. E., Hokke, C. H., Smits, H. H. & Hoene, E. N. M. N. ' . Pathogen-Derived Extracellular Vesicle-Associated Molecules That Affect the Host Immune System: An Overview. *Frontiers in Microbiology* **9**, 2182 (2018).
- Whitehead, B., Boysen, A. T., Mardahl, M. & Nejsun, P. Unique glycan and lipid composition of helminth-derived extracellular vesicles may reveal novel roles in host-parasite interactions. *International Journal for Parasitology* **50**, 647–654 (2020).

16. Macedo-da-Silva, J., Santiago, V. F., Rosa-Fernandes, L., Marinho, C. R. F. & Palmisano, G. Protein glycosylation in extracellular vesicles: Structural characterization and biological functions. *Mol Immunol* **135**, 226–246 (2021).
17. Van Deun, J. *et al.* EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. *Nat Methods* **14**, 228–232 (2017).
18. Kuipers, M. E. *et al.* Optimized Protocol for the Isolation of Extracellular Vesicles from the Parasitic Worm *Schistosoma mansoni* with Improved Purity, Concentration, and Yield. *J Immunol Res* **2022**, 5473763 (2022).
19. Petralia, L. M. C. *et al.* Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode *Brugia malayi* Glycome Reveals Anionic and Zwitterionic Glycan Antigens. *Mol Cell Proteomics* **21**, 100201 (2022).
20. Ceroni, A. *et al.* GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. *J Proteome Res* **7**, 1650–1659 (2008).
21. Smit, C. H. *et al.* Surface expression patterns of defined glycan antigens change during *Schistosoma mansoni* cercarial transformation and development of schistosomula. *Glycobiology* **25**, 1465–1479 (2015).
22. van Remoortere, A. *et al.* *Schistosoma mansoni*-infected mice produce antibodies that cross-react with plant, insect, and mammalian glycoproteins and recognize the truncated biantennary N-glycan Man3GlcNAc2-R. *Glycobiology* **13**, 217–225 (2003).
23. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**, 676–682 (2012).
24. van Vliet, S. J. *et al.* Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells. *Int Immunol* **17**, 661–669 (2005).
25. Geijtenbeek, T. B. H. *et al.* Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. *Cell* **100**, 575–585 (2000).
26. van Die, I. *et al.* The dendritic cell-specific C-type lectin DC-SIGN is a receptor for *Schistosoma mansoni* egg antigens and recognizes the glycan antigen Lewis x. *Glycobiology* **13**, 471–478 (2003).
27. van Kooyk, Y., Ilarregui, J. M. & van Vliet, S. J. Novel insights into the immunomodulatory role of the dendritic cell and macrophage-expressed C-type lectin MGL. *Immunobiology* **220**, 185–192 (2015).
28. Sotillo, J. *et al.* Extracellular vesicles secreted by *Schistosoma mansoni* contain protein vaccine candidates. *Int J Parasitol* **46**, 1–5 (2016).
29. Samoil, V. *et al.* Vesicle-based secretion in schistosomes: Analysis of protein and microRNA (miRNA) content of exosome-like vesicles derived from *Schistosoma mansoni*. *Sci Rep* **8**, 3286 (2018).
30. Meninger, T. *et al.* Schistosomal MicroRNAs Isolated From Extracellular Vesicles in Sera of Infected Patients: A New Tool for Diagnosis and Follow-up of Human Schistosomiasis. *J Infect Dis* **215**, 378–386 (2017).
31. Kifle, D. W. *et al.* Proteomic analysis of two populations of *Schistosoma mansoni*-derived extracellular vesicles: 15k pellet and 120k pellet vesicles. *Mol Biochem Parasitol* **236**, 111264 (2020).

32. Dagenais, M. *et al.* Analysis of schistosoma mansoni extracellular vesicles surface glycans reveals potential immune evasion mechanism and new insights on their origins of biogenesis. *Pathogens* **10**, (2021).
33. Hokke, C. H. & van Diepen, A. Helminth glycomics – glycan repertoires and host–parasite interactions. *Mol Biochem Parasitol* **215**, 47–57 (2017).
34. Dagenais, M., Gerlach, J. Q., Geary, T. G. & Long, T. Sugar Coating: Utilisation of Host Serum Sialoglycoproteins by *Schistosoma mansoni* as a Potential Immune Evasion Mechanism. *Pathogens* **11**, 426 (2022).
35. Gasan, T. A. *et al.* *Schistosoma mansoni* Larval Extracellular Vesicle protein 1 (SmLEV1) is an immunogenic antigen found in EVs released from pre-acetabular glands of invading cercariae. *PLOS Neglected Tropical Diseases* **15**, e0009981 (2021).
36. Samuelson, J. C. & Caulfield, J. P. The cercarial glycocalyx of *Schistosoma mansoni*. *J Cell Biol* **100**, 1423–1434 (1985).
37. Schmidt, J. Glycans with N-acetylglucosamine type 2-like residues covering adult *Schistosoma mansoni*, and glycomimesis as a putative mechanism of immune evasion. *Parasitology* **111** (Pt 3, 325–336 (1995).
38. Tran, M. H. *et al.* Tetraspanins on the surface of *Schistosoma mansoni* are protective antigens against schistosomiasis. *Nat Med* **12**, 835–840 (2006).
39. Drurey, C., Coakley, G. & Maizels, R. M. Extracellular vesicles: new targets for vaccines against helminth parasites. *Int J Parasitol* **50**, 623–633 (2020).
40. Buzas, E. I. Opportunities and challenges in studying the extracellular vesicle corona. *Nat Cell Biol* **24**, 1322–1325 (2022).
41. Zeev-Ben-Mordehai, T., Vasishtan, D., Siebert, C. A., Whittle, C. & Grünewald, K. Extracellular Vesicles: A Platform for the Structure Determination of Membrane Proteins by Cryo-EM. *Structure* **22**, 1687–1692 (2014).
42. Sánchez-López, C. M. *et al.* Diversity of extracellular vesicles from different developmental stages of *Fasciola hepatica*. *Int J Parasitol* **50**, 663–669 (2020).
43. Rizzo, J. *et al.* Revisiting *Cryptococcus* extracellular vesicles properties and their use as vaccine platforms. *bioRxiv* 2020.08.17.253716 (2021) doi:10.1101/2020.08.17.253716.
44. Gui, M. J., Dashper, S. G., Slakeski, N., Chen, Y. Y. & Reynolds, E. C. Spheres of influence: Porphyromonas gingivalis outer membrane vesicles. *Molecular Oral Microbiology* **31**, 365–378 (2016).
45. Cecil, J. D. *et al.* Outer Membrane Vesicle–Host Cell Interactions. *Microbiology Spectrum* **7**, 7.1.06 (2019).
46. Geijtenbeek, T. B. & Gringhuis, S. I. C-type lectin receptors in the control of T helper cell differentiation. *Nat Rev Immunol* **16**, 433–448 (2016).
47. Figliuolo da Paz, V. R., Figueiredo-Vanzan, D. & Dos Santos Pyrrho, A. Interaction and involvement of cellular adhesion molecules in the pathogenesis of Schistosomiasis mansoni. *Immunol Lett* **206**, 11–18 (2019).
48. Mountford, A. P. & Trottein, F. Schistosomes in the skin: a balance between immune priming and regulation. *Trends Parasitol* **20**, 221–226 (2004).

49. van Vliet, S. J. *et al.* MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF- α secretion. *J Leukoc Biol* **94**, 315–323 (2013).
50. Hirata, Y., Ihara, S. & Koike, K. Targeting the complex interactions between microbiota, host epithelial and immune cells in inflammatory bowel disease. *Pharmacol Res* **113**, 574–584 (2016).
51. Valverde, P., Martínez, J. D., Cañada, F. J., Ardá, A. & Jiménez-Barbero, J. Molecular Recognition in C-Type Lectins: The Cases of DC-SIGN, Langerin, MGL, and L-Sectin. *Chembiochem* **21**, 2999–3025 (2020).
52. Brockhausen, I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. *EMBO Rep* **7**, 599–604 (2006).
53. Maizels, R. M. & McSorley, H. J. Regulation of the host immune system by helminth parasites. *Journal of Allergy and Clinical Immunology* **138**, 666–675 (2016).
54. Raes, G. *et al.* Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. *J Leukoc Biol* **77**, 321–327 (2005).
55. Costain, A. H., MacDonald, A. S. & Smits, H. H. Schistosome Egg Migration: Mechanisms, Pathogenesis and Host Immune Responses. *Front Immunol* **9**, 3042 (2018).
56. Meevissen, M. H. J. *et al.* Specific glycan elements determine differential binding of individual egg glycoproteins of the human parasite *Schistosoma mansoni* by host C-type lectin receptors. *Int J Parasitol* **42**, 269–277 (2012).
57. Mekonnen, G. G. *et al.* *Schistosoma haematobium* Extracellular Vesicle Proteins Confer Protection in a Heterologous Model of Schistosomiasis. *Vaccines (Basel)* **8**, (2020).
58. Kifle, D. W. (2020). *Schistosoma mansoni* extracellular vesicles: immunobiology and vaccine efficacy. [Dissertation Thesis] [Queensland, Australia]: James Cook University, College of Public Health, Medical and Veterinary Sciences Centre for Molecular Therapeutics Australian Institute of Tropical Health and Medicine doi: 10.25903/fhzh-2h14.

Supplementary Figures




Supplementary Figure S1. MS/MS fragmentation of 1582 m/z to confirm LDN antenna

MS/MS fragmentation of 1582 m/z by MALDI-TOF/TOF of PNGase F released and AA-labeled N-glycans of adult worm EVs to confirm the presence of a single LDN antenna. Peaks are labelled with their monoisotopic masses. Green circle, mannose; yellow circle, galactose; blue square, N-acetylglucosamine; yellow square, N-acetylgalactosamine; red triangle, fucose.



← **Supplementary Figure S2. Western blots of EV-associated glycoconjugates and their analysis by ImageJ.**

Analysis workflow of measured blots in ImageJ (A). Area under the curve of the 12 gradient fractions were added together to form one number, EV-depleted (100k sup) supernatant had its own number. Full western blots of each antibody and life stage (B). Blots are representative for 2-3 biological replicates. 273-3F2 detects LDN; 100-4G11 detects tri-mannosyl core; 290-2E6 detects LDN-F; 128-1E7 detects F-GlcNAc, F-LDN, and F-LDN-F; 258-3E3 detects F-GlcNAc; 114-4D12 detects DF-GlcNAc and TF-GlcNAc; 291-5D5 detects F-LDN and F-LDN-F. Full description of these glycans and their linkage can be found in the legend of table 1.



Supplementary Figure S3. MGL and DC-SIGN receptor expression on CLR expressing cell lines.

CHO (MGL) and K562 (DC-SIGN) without the CLR vector are shown in grey.